Remedium Bio Secures $10 Million Series A Led by Lifespan Vision Ventures with Lilly Participation to Advance Adjustable Gene Therapy Platform
核心洞察
Remedium Bio (搜索) announced the initial closing of a $10 million Series A financing round led by Lifespan Vision Ventures (搜索), with participation from Eli Lilly and Company and HKX Capital (搜索).
The company's Prometheus™ platform uses adipocytes at subcutaneous injection sites to produce therapeutic proteins for years, with the ability to adjust expression after treatment.
Proceeds will support advancement of lead programs toward first-in-human clinical studies, platform expansion, and pipeline development across cardiometabolic and other chronic diseases.
Remedium Bio (搜索), Inc. has announced the initial closing of a planned $10 million Series A financing round, marking a significant step toward bringing its adjustable, durable gene therapy platform into clinical development. The round is led by Lifespan Vision Ventures (搜索), with participation from Eli Lilly and Company and HKX Capital (搜索). In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors. The company expects to complete the round with a further group of investors before final close.
The Boston-based biotechnology company is developing what it describes as a fundamentally different approach to chronic disease treatment: converting fat cells into long-term, controllable producers of therapeutic proteins through a single, minimally invasive subcutaneous injection.
The Prometheus™ Platform: Turning Adipocytes into Drug Factories
Remedium's proprietary Prometheus™ platform harnesses adipocytes—fat cells—at the site of injection as durable sites for therapeutic protein production. Rather than requiring patients to receive repeated administrations of protein-based biologics, the platform delivers genetic instructions that enable the patient's own cells to manufacture the therapeutic protein, potentially for years.
Crucially, the company emphasizes that expression can be adjusted after treatment according to therapeutic need—a feature designed to address one of gene therapy's most persistent challenges: the inability to modify dosing once a therapy has been administered.
"Our leverage comes in part from localizing treatment to adipocytes at the injection site and administering it through a minimally invasive subcutaneous injection," said Frank Luppino, CEO and co-founder of Remedium Bio (搜索). "This is designed to reduce systemic exposure while using an accessible and well-characterized tissue to produce the intended therapeutic protein."
Addressing the Limitations of Chronic Biologic Therapy
The platform targets a well-recognized problem in chronic disease management: even highly effective biologic therapies are of limited utility when patients cannot or do not remain adherent to regular dosing schedules. Repeated administration also creates peaks and troughs in drug exposure, logistical burden, and accumulating healthcare costs over decades of treatment.
"The shift would be fundamental," Luppino said of converting chronic protein delivery into a single, multi-year intervention. "Today, even highly effective preventive medicines depend on patients taking them week after week, often for decades."
The company sees cardiometabolic disease—particularly obesity (搜索) and type 2 diabetes (搜索)—as an early opportunity for the platform. Both conditions can emerge relatively early in the trajectory of age-related multimorbidity and increase subsequent risks across cardiovascular, renal, and functional health. "Improving metabolic health earlier and more consistently could therefore deliver benefits across multiple dimensions of healthspan," Luppino noted, adding that cardiometabolic health represents "the first and most immediate opportunity—not the limit of the platform."
A Different Economic Model for Gene Therapy
Remedium argues that its approach could reshape the economics of gene therapy. Historically, gene therapies have been developed around small patient populations with correspondingly substantial price tags, while protein biologics for common chronic diseases operate at an altogether different scale.
"By overcoming these technical constraints and designing therapies for large patient populations, we can pursue a different economic model," Luppino said. "Manufacturing and development costs can be distributed across larger markets, creating economies of scale that have historically been unavailable to orphan-focused gene therapies."
Investor Confidence and Next Steps
"Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy," said Andrew Worden, Founding Partner of Lifespan Vision Ventures (搜索). "We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform."
The financing follows recent progress across Remedium's pipeline, strategic collaborations, and preclinical programs. The company's pipeline spans endocrinology, immunology, neurology, and musculoskeletal diseases. Proceeds from the Series A are expected to support key milestones demonstrating the breadth of the platform across cardiometabolic and other chronic diseases, as well as preparation for first-in-human clinical studies.
"We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development," said Luppino.
As Remedium approaches first-in-human studies, the central question will be whether the platform's adjustable expression can be maintained at therapeutically useful levels with sufficient precision and an acceptable safety profile over extended periods—moving from an elegant engineering proposition to clinical evidence.